The standard treatment for HFpEF includes sodium-glucose cotransporter 2 inhibitors (SGLT2i), such as empagliflozin and dapagliflozin, supported by the EMPEROR-Preserved (2021) and DELIVER (2022) trials [7, 8]
Hjberg PV, Vilsbll T, Rabl R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S
As nausea and reduced appetite become less pronounced, patients typically find it easier to maintain adequate nutrition and hydration, which supports energy levels
It contributes to detoxification, promotes the proper functioning of the liver and promotes intestinal comfort
What Is the Current Research Focus of FOXO4-DRI
N-acetylcysteine augmentation in treatment-resistant obsessive-compulsive disorder: A case series